Hypertension is one of the most powerful modifiable risk factors for cardiovascular disease. It is usually asymptomatic and therefore essential to measure blood pressure regularly for the detection of hypertension. Home blood pressure monitoring (HBPM) is recognized as a valuable tool to monitor blood pressure and facilitate effective diagnosis of hypertension. It is useful to identify the masked or white-coat hypertension. There is also increasing evidence that supports the role of HBPM in guiding antihypertensive treatment, and improving treatment compliance and hypertension control. In addition, HBPM has also shown prognostic value in predicting cardiovascular events. Despite these benefits, the use of HBPM in many parts of Asia has been reported to be low. An expert panel comprising 12 leading experts from 10 Asian countries/regions convened to share their perspectives on the realities of HBPM. This article provides an expert summary of the current status of HBPM and the key factors hindering its use. It also describes HBPM-related initiatives in the respective countries/regions and presents strategies that could be implemented to better support the use of HBPM in the management of hypertension.
Bibliographical noteFunding Information:
Jiguang WANG received grants from Bayer, Chengdu DiAo, MSD, and Beijing ShuangHe, and lecture and consulting fees from AstraZeneca, Bayer, Omron Healthcare, Salubris, Servier, and Takeda. Yook Chin CHIA received grants from Pfizer and Omron Healthcare for Young Investigators' Network, and speaker honoraria from Pfizer, Servier, and Omron Healthcare. Kazuomi KARIO received grants and lecture fees from Omron Healthcare. Takayoshi OHKUBO and Jam Chin Tay received grants from Omron Healthcare. Tzung‐Dau WANG received research grants from Novartis and Omron Healthcare, and honoraria for lectures and consultations from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron Healthcare, Pfizer, Sanofi, and Servier. The rest of the authors declare no conflict of interest.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine